GSK plc reported on May 8, 2025, positive results from the GLISTEN phase III trial showing that linerixibat significantly improves itching in patients with primary biliary cholangitis, with a notable 72% decrease in itch scores compared to placebo. The drug is currently not approved and aims to address a major symptom in this patient population.